M&A / Deals Aditxt and Ignite announce merger plans with strategic partner Pharmaceutical TechnologyAditxt and subsidiary Ignite Proteomics have announced plans for a business combination with a strategic partner.Read full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaceutical Technology Aditxt and subsidiary Ignite Proteomics have announced plans for a business combination with a strategic partner. Read full story Post navigation Previous: Cancer biotech Parabilis books record IPO, raising $670mNext: AbbVie’s migraine drug cleared for migraine attacks on NHS Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026